Many tumour- and bone-derived factors that have been implicated in the pathogenesis of breast cancer bone metastases including receptor activator of NFκB ligand (RANKL) and interleukin-1 (IL-1) activate NFκB [12–14]. This evidence concerns the gene NFKB1 and neoplasm.